Enovis Corporation
Rank #168StartupENOV · NYSE · Healthcare
Enovis Corporation (ENOV) — Rank #168 by gross profitability (GP/assets 0.36) · ROE -80.2% · Piotroski F-Score 4 / 9.
As-of 2026-09-15 · CIK 0001420800 · all metrics point-in-time as of the filing date.
About
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Show moreShow less
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation.
Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- enovis.com
Price History
Company Snapshot
P/S is the primary valuation lens for pre-profit companies.
Market Cap
$1.06B
P/E (annual)
—
P/S (annual)
0.5
P/B
0.7
P/OCF (annual)
4.9
Shareholder Yield
-3.2%
Employees
7,802
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
20.9%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 3.2% — per-share value needs a total required return of 24.1% once share-count change is priced in.
vs. own 6-year median revenue growth: 9.4%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
15.8%
r = 10% (base)
20.9%
r = 12%
25.3%
Net debt / market cap: 121.7%— material leverage inflates the implied growth read.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Burn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.
Profitability
Gross profitability (GP / assets)
0.36
Primary signal (Novy-Marx).
56th pctl of 37 SIC 38 peers
Return on equity
-80.2%
Gross margin
59.8%
47th pctl of 37 SIC 38 peers
Revenue growth (YoY)
6.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
12.9%
Revenue CAGR (5Y)
14.9%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.55
9th pctl of 35 SIC 38 peers (best = lowest)
Current ratio
1.98×
31st pctl of 36 SIC 38 peers
Quick ratio
0.74×
Net cash
-$1.27B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$19.92M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.02
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
4 / 9
Fundamental-strength score (0-9).
Lifecycle Phase History
Lynch sell alert: Fast grower deceleration
Revenue growth decelerated to 6.7% after being classified hypergrowth as of 2024-12-31 -- Lynch's fast-grower rule: sell once growth slows below the pace that justified the label, not on price weakness.